CMPX Logo

Compass Therapeutics, Inc. (CMPX) 

NASDAQ
Market Cap
$251.79M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
496 of 776
Rank in Industry
265 of 433

Largest Insider Buys in Sector

CMPX Stock Price History Chart

CMPX Stock Performance

About Compass Therapeutics, Inc.

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137. Its product …

Insider Activity of Compass Therapeutics, Inc.

Over the last 12 months, insiders at Compass Therapeutics, Inc. have bought $0 and sold $0 worth of Compass Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Compass Therapeutics, Inc. have bought $14.88M and sold $103,708 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 10,000 shares for transaction amount of $33,700 was made by Schuetz Thomas J. (CHIEF EXECUTIVE OFFICER) on 2023‑03‑10.

List of Insider Buy and Sell Transactions, Compass Therapeutics, Inc.

2023-03-10PurchaseCHIEF EXECUTIVE OFFICER
10,000
0.008%
$3.37$33,700-31.63%
2023-02-27PurchaseCHIEF EXECUTIVE OFFICER
20,000
0.016%
$3.98$79,600-39.44%
2023-02-15PurchaseCHIEF EXECUTIVE OFFICER
20,000
0.0153%
$3.86$77,200-38.82%
2023-01-31PurchaseCHIEF EXECUTIVE OFFICER
20,000
0.016%
$4.05$81,000-35.38%
2023-01-24PurchaseCHIEF EXECUTIVE OFFICER
20,000
0.0158%
$4.19$83,800-37.05%
2022-11-25SaleChief Operating Officer
2
<0.0001%
$4.36$9-28.83%
2022-11-23SaleChief Operating Officer
9,569
0.0088%
$4.30$41,147-29.89%
2022-11-22SaleChief Operating Officer
14,929
0.0139%
$4.19$62,553-27.27%
2022-11-08Purchasedirector
402,000
0.2887%
$3.21$1.29M-25.18%
2022-11-08Purchasedirector
402,000
0.2887%
$3.21$1.29M-25.18%
2022-09-07PurchaseCHIEF EXECUTIVE OFFICER
15,000
0.0148%
$3.03$45,450+4.92%
2022-09-01PurchaseCHIEF EXECUTIVE OFFICER
15,000
0.0145%
$2.83$42,450+10.34%
2022-08-17PurchaseCHIEF EXECUTIVE OFFICER
15,000
0.0151%
$3.05$45,750+6.67%
2022-08-10PurchaseCHIEF EXECUTIVE OFFICER
15,000
0.0146%
$2.64$39,600+19.40%
2022-08-01PurchaseCHIEF EXECUTIVE OFFICER
15,000
0.0145%
$2.58$38,700+21.21%
2022-06-21PurchaseCHIEF EXECUTIVE OFFICER
20,000
0.019%
$2.80$56,000+9.25%
2022-06-16PurchaseCHIEF EXECUTIVE OFFICER
20,000
0.0188%
$2.34$46,800+28.74%
2022-06-13PurchaseCHIEF EXECUTIVE OFFICER
30,000
0.0339%
$2.29$68,700+57.71%
2022-06-06PurchaseCHIEF EXECUTIVE OFFICER
30,000
0.0304%
$2.83$84,900+14.08%
2022-06-01PurchaseCHIEF EXECUTIVE OFFICER
20,000
0.0206%
$3.03$60,600+8.22%

Insider Historical Profitability

12.91%
ORBIMED ADVISORS LLCdirector
15219994
11.0619%
$1.8330<0.0001%
GORDON CARL Ldirector
15219994
11.0619%
$1.8350+26.53%
OrbiMed Genesis GP LLC
14690178
10.6769%
$1.8320+76.65%
Schuetz Thomas J.CHIEF EXECUTIVE OFFICER
6021873
4.3767%
$1.83200+7.18%
Sunderland Juliedirector
2502025
1.8185%
$1.8310

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
OrbiMed$44.28M16.2522.36M0%+$00.34
Adage Capital Partners Gp L L C$22.04M8.0911.13M+12.65%+$2.48M0.04
Janus Henderson$12.82M4.726.49M-0.83%-$107,303.750.01
Blackstone$12.26M4.56.19M0%+$00.05
BlackRock$11.94M4.386.03M-3.05%-$375,889.15<0.0001
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.